The ALS Emergency Treatment Fund (ALS-ETF) and Denovo Biomarkers are partnering in a pharmacogenomics-based effort to identify potential responder groups for drugs being studied in amyotrophic lateral sclerosis patients.
Through this partnership, the firms will use Denovo technology to analyze samples obtained from expanded access programs that ALS-ETF sponsors with the hopes of identifying genomic biomarkers that correlate with treatment response, the firms said. Financial terms of the agreement were not disclosed.
In a statement, Denovo CSO Wen Luo noted: "This partnership leverages the mission of ALS-ETF and the broad utility of our platform. We hope that our combined efforts will lead to better, more targeted treatments for ALS."